BINV — BioInvent International AB Share News
0.000.00%
Last trade - 00:00- SEK1.59bn
- SEK1.14bn
- SEK226.50m
Brief: CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL In China
Brief: Bioinvent Submits CTA For Phase 1/2A Trial Of Bi-1607, Novel Anti-FcyRIIB Antibody
Brief: Transgene/BioInvent: positive data regarding their BT-001 product
Brief: Casi Pharmaceuticals Partner, Bioinvent, To Present Further Positive Clinical Data On BI-1206 At Ash 2021
Brief: BioInvent Reports Positive BI-1206 Clinical Data
Brief: Bioinvent Q2 Loss After Tax Widens To SEK 57.3 Million
Brief: BioInvent Gets Notice Of Allowance In China
Brief: Bioinvent And Transgene Receive Approval From FDA For Bt-001
Brief: Transgene And Bioinvent Receive IND Approval From FDA For BT-001
Brief: Bioinvent Q1 Loss After Tax Widens To SEK 79.8 Million
Brief: Bioinvent's Partner Oncurious NV Presents Phase I Data On TB-403
Brief: Bioinvent Gets IND Approval For Phase I/IIa Trial Of Anti-TNFR2 Antibody BI-1808
Brief: Transgene And BioInvent Enrol First Patient In Phase I/IIa Of Oncolytic Virus BT-001 Trial
Brief: Bioinvent Q4 Result After Tax Swings To Profit Of SEK 28.5 Million
Brief: Bioinvent Successfully Carries Out A Directed Share Issue Of Approximately SEK 962 Million
Brief: CASI Pharmaceuticals Partner, Bioinvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients
Brief: Bioinvent: Positive Interim Results From The Phase I/IIa Trial
Brief: Transgene, Bioinvent Get ANSM Approval For Phase I/IIa Trial
Brief: Bioinvent Streamlines Agreement On Anti-Fcγrllb Antibody